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CME Objective for This Article:
1. Describe the MACCE outcomes of patients undergoing unprotected left main revascularization using EES to SES and to CABG surgery. 2. Compare the composite incidence of death, MI, and stroke in patients undergoing unprotected left main revascularization using EES to SES and to CABG surgery. 3. Compare the rates of ischemia-driven TVR in patients undergoing unprotected left main revascularization using EES to SES and to CABG surgery.
Everolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis
The Objectives This study sought to evaluate the safety and efficacy of second-generation drug-eluting stents (DES) for patients with unprotected left main coronary artery (ULMCA) stenosis.
Background The clinical benefit of second-generation DES for ULMCA stenosis has not been determined.
Methods The authors assessed 334 consecutive patients who received everolimus-eluting stents (EES) for ULMCA stenosis between 2009 and 2010. The 18-month incidence rates of major adverse cardiac or cerebrovascular events (MACCE), including death, myocardial infarction (MI), stroke, or ischemia-driven target vessel revascularization (TVR), were compared with those of a randomized study comparing patients who received sirolimus-eluting stents (SES) (n ϭ 327) or coronary artery bypass grafts (CABG) (n ϭ 272).
Results EES (8.9%) showed a comparable incidence of MACCE as SES (10 was noninferior to CABG in terms of 1-year incidence of major adverse cardiac or cerebrovascular events (MACCE) (12) . These results have led to recently updated recommendations that PCI may be considered an alternative to surgery in patients who are not at high risk (14, 15) . Despite these results, certain clinical issues regarding the safety of first-generation DES for treatment of ULMCA stenosis remain unresolved. Although stent thrombosis is rare, its rate continues to increase and has been associated with fatal consequences (16) . Moreover, the need for repeat revascularization remains higher after DES than after CABG (6, 12, 13 (12) .
Methods
Study population. Between May 2009 and September 2010, 392 patients underwent ULMCA stenting with EES in 21 Korean cardiac centers; of these patients, 334 who met the inclusion and exclusion criteria of the PRECOMBAT randomized trial (12) were entered into the prospective PRECOMBAT-2 registry study. The inclusion and exclusion criteria of PRECOMBAT have been described (12) . In brief, the trial included patients with angiographic UL-MCA stenosis (Ͼ50% stenosis), who did not have STsegment elevation myocardial infarction (MI), cardiogenic shock, another serious comorbidity, or contraindication to DES. The institutional review board of each center approved the use of clinical data for this study, and all patients provided written informed consent. Procedures. PCI procedures were performed in a standardized manner (12) . To decrease the influence of selection bias between EES patients and the historical controls of SES and CABG patients, EES were used as the default stent for all patients treated for ULMCA stenosis at the investigating sites during the study period. We attempted to treat all lesions using SES in the PRECOMBAT study and EES in the PRECOMBAT-2 study. The maximum length and diameter of SES were 33 and 3.5 mm, respectively, and the maximum length and diameter of EES were 28 and 4.0 mm, respectively. Use of intravascular ultrasound, adjunctive devices, or glycoprotein IIb/IIIa inhibitors was at the operator's discretion. All patients were prescribed aspirin plus clopidogrel before or during the procedure. After PCI, all patients received 100 mg/day aspirin indefinitely and 75 mg/day clopidogrel for at least 1 year. Endpoints and definitions. The primary endpoint was MACCE, including death from any cause, MI, stroke, or ischemia-driven target vessel revascularization (TVR) after the procedure. The definitions of endpoints were identical to those in the PRECOMBAT study (12) . Deaths were considered cardiac unless an unequivocal, noncardiac cause was established. MI was defined as new Q waves and an increase in creatine kinase-myocardial band concentration to Ͼ5 times the upper limit of the normal range, if occurring within 48 h after the procedure, or as new Q waves or an increase in creatine kinase MB concentration to greater than the upper limit of the normal range, plus ischemic symptoms or signs, if occurring more than 48 h after the procedure. Stroke was defined as a neurological symptom resulting from vascular lesions of the brain, persisting for Ͼ24 h. TVR, consisting of repeat revascularization of the treated vessel with either PCI or CABG, was considered ischemia driven if the stenosis of any vessel was at least 50% of the diameter of the vessel in the presence of ischemic signs or symptoms or if the stenosis was at least 70% of the diameter of the vessel in the absence of ischemic signs or symptoms. Clinically driven TVR was considered when the treated vessels had stenosis of at least 50% in the presence of ischemic signs or symptoms. An independent clinical events committee adjudicated all primary clinical endpoints. Adverse events were assessed in the hospital, at 30 days, and at 6, 9, and 12 months. Patients were asked to return for follow-up angiography 8 to 10 months after the PCI, or earlier if angina symptoms occurred. However, due to the tendency of in-stent restenosis having a benign presentation in patients with ULMCA, angiographic surveillance was less strongly recommended in the PRECOMBAT-2 than in the PRECOMBAT study (19) . The updated guideline does not recommend routine angiographic follow-up because of its limited ability to predict stent thrombosis and good intermediate-term outcomes after ULMCA stenting (15) . Angiographic analysis. Available angiograms were independently analyzed at the angiographic core laboratory (CardioVascular Research Foundation, Seoul, Korea). Quantitative angiographic parameters, including minimal lumen diameter (MLD), reference artery diameter, diameter stenosis (DS), lesion length, and late luminal loss, were measured at baseline, after the procedure, and during follow-up in the main branch, including segments of the left main and proximal left anterior descending artery (LAD) and the side branch (usually the left circumflex artery) using dedicated bifurcation angiographic software (CAAS version 5.4, Pie Medical, Maastricht, the Netherlands) (20) . When the left main lesion did not involve bifurcation stenosis, analysis included the left main segment. Angiographic restenosis was defined as Ͼ50% DS within the stented segment, including the stent and the 5-mm proximal and distal segments, on follow-up angiography. Patterns of angiographic restenosis were quantitatively assessed using the Mehran classification (21). Statistical analysis. As-treated groups were compared, regardless of assigned randomization in the PRECOMBAT study. We included patients comparable to the number of patients in the PRECOMBAT study without sample size justification. Clinical and angiographic characteristics are presented as number and percentage or as mean Ϯ SD. For continuous variables, differences among the 3 treatment groups (EES, SES, and CABG) were evaluated by analysis of variance, whereas differences between 2 groups (EES and SES) were analyzed by Student t test. Differences in categorical variables were analyzed using the chi-square test or Fisher exact test, as appropriate. The clinical endpoints were compared using a log-rank test of time to first event Values are mean Ϯ SD, n (%), or n/n (%). EES patients were enrolled in the PRECOMBAT-2 study and SES patients in the historical control of PRECOMBAT study.
DS ϭ diameter stenosis; LAD ϭ left anterior descending coronary artery; MLD ϭ minimal lumen diameter; other abbreviations as in Table 1 .
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from the time of the procedure. The Kaplan-Meier method was used to estimate survival. Patients were censored at 18 months or at occurrence of an endpoint. Differences among the groups in risk-adjusted, long-term rates of study outcomes were assessed using multivariable Cox proportional hazards regression with covariates that had a significant effect (p Ͻ 0.1) on clinical outcomes. Covariates considered in the Cox models included patient age and sex; presence of hypertension, smoking, hypercholesterolemia, and diabetes mellitus; prior history of MI, stroke, peripheral vascular disease, congestive heart failure, chronic renal failure, chronic lung disease, bifurcation left main stenosis, multivessel disease, and PCI; performance of angiographic surveillance; and left ventricular ejection fraction. The multivariate models were confirmed by backward elimination. The proportional hazards assumption was confirmed by testing of partial (Schoenfeld) residuals, and no relevant violations were found (22) . No adjustments were made for multiple comparisons in post hoc secondary analyses. SAS software, version 9.1, was used for all statistical analyses (SAS Institute Inc., Cary, North Carolina).
Results
Study patients. Baseline characteristics and procedural findings are shown in (Table 2) . However, DS in the side branch and lesion length in the main branch were less severe in EES than SES patients. Clinical outcomes. Table 3 and Figure 1 show clinical outcomes over 18 months. Before adjustment, the 3 groups had comparable incidence rates of individual endpoints and the composite of death, MI, or stroke. However, the incidence of ischemia-driven TVR was lower in the CABG than in the SES or EES group, but the clinically driven TVR rate did not differ significantly. The overall incidence of MACCE, the primary endpoint, did not differ among the 3 groups. There were no differences in clinical outcomes between the SES and EES groups. When the risks of events were adjusted using the Cox proportional hazard model, the pattern of differences in clinical outcomes did not change (Fig. 2) Table 2 shows the quantitative angiographic outcomes in the SES and EES groups. After the procedure, EES patients achieved lower DS in the main branch, but higher DS in the side branch, than SES patients. Quantitative angiographic analyses at follow-up were performed in 73% of SES and 59% of EES patients, but there were no between-group differences in angiographic parameters, including DS, MLD, and late loss in any segment. Subsequently, the rate of overall restenosis did not differ between the 2 groups. However, late loss and restenosis rates in the main branch were slightly lower in EES than in SES patients. In both groups, a focal pattern was predominant in restenotic lesions.
Angiographic and clinical outcomes according to the stent
technique. When the stenting technique was separated into the single-and 2-stent techniques, kissing stenting technique and crush technique were most popularly used in SES and EES patients, respectively ( Table 1 ). The restenosis rates in the subgroups stratified by the stent technique are illustrated in Figure 3 . Ischemia-driven TVR occurred in 11 (5.3%) SES and 12 (5.1%) EES patients in the single-stent group (log-rank p ϭ 0.94) and 15 (13.6%) SES and 9 (10.4%) EES patients in the 2-stent group (log-rank p ϭ 0.51). Among them, TVR at left main was included in 5 SES and 12 EES patients in the single-stent group and in 11 SES and 9 EES patients in the 2-stent group.
Discussion
The major finding of this study is that using EES for ULMCA stenosis is as safe and effective as employing SES or CABG, as shown by the 18-month incidence of MACCE. Although the need for repeat revascularization was higher after EES than after CABG, second-generation EES had risks of angiographic and clinical restenosis comparable to those of first-generation SES. Most studies evaluating the long-term outcomes of PCI using DES for ULMCA stenosis have used first-generation SES or paclitaxel-eluting stents (1-12) . Previous randomized and registry studies found that these DES had similar long-term safety and efficacy results (7, 23) . Despite the trend toward higher late loss after paclitaxel-eluting stent implantation, their clinical outcomes, including rates of repeat revascularization, were similar. Nonetheless, PCI for ULMCA stenosis, particularly with bifurcation involvement, remains technically challenging and is related to higher rates of stent thrombosis and repeat revascularization. Therefore, studies assessing the safety and efficacy of second-generation DES relative to first-generation DES for ULMCA stenosis appear worthwhile. Compared with SES, the reduced strut thickness (81 vs. 140 m) and thinner polymer coating (7.6 vs. 12.6 m), in conjunction with improved biocompatibility of the EES polymer, may favorably affect neointimal hyperplasia. In addition, the availability of a 4.0-mm EES stent might have achieved better stent expansion and drug diffusion. In the PRECOMBAT study, the maximal size of the SES used was 3.5 mm even in the big left main lesions. Our study has the advantage of comparing the outcomes of second-generation EES with those of first-generation SES and CABG. Despite our nonrandomized study design, the 3 patient groups-those treated with EES in the PRECOMBAT-2 trial and those treated with SES and CABG in the PRECOMBAT study-were comparable, without a serious selection bias, since both trials used the same inclusion and exclusion criteria.
We found that the clinical and angiographic outcomes of patients with ULMCA stenosis treated with secondgeneration EES and first-generation SES were comparable over 18 months. These 2 types of stents were recently compared in patients with unselected lesions. For example, the randomized ESSENCE-DIABETES (EverolimusEluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus) trial, involving 300 diabetic patients, found a tendency toward lower restenosis rate, but similar clinical outcomes, in the EES compared with the SES group (24) . Another large, as yet unpublished trial, SORT OUT IV (the Scandinavian Organisation for Randomised Trials with Clinical Outcome IV) study, involving 2,774 unselected patients, found that EES and SES yielded similar 9-month incidence rates of death, MI, stent thrombosis, and TVR (25) . The similar clinical outcomes of SES and EES in these studies, as well as in ours, may be due primarily to the comparable biological potency of everolimus and sirolimus. Alternatively, as suggested in studies comparing SES and paclitaxel-eluting stents for ULMCA stenosis, large caliber in the left main coronary artery may accommodate the impact of intimal tissue growth on net clinical outcomes if similar stenting techniques are used (7, 19) . Nonetheless, our finding of a slightly lower late loss and restenosis rate in the main branch after EES implantation suggests that different DES have different efficacies for ULMCA stenosis. Further studies evaluating the angiographic and clinical outcomes achieved using various DES should clarify their differential efficacies. PCI using EES had a similar incidence of death, MI, or stroke, but a higher incidence of TVR, compared with CABG. This pattern was in agreement with findings comparing PCI using first-generation DES and CABG in the PRECOMBAT and other trials (12, 13) . However, the rate of clinically driven TVR, which excluded revascularizations for patients without objective recurrence of ischemic symptom or sign, did not differ significantly between EES and CABG patients. This indicates that the "oculostenotic reflex" due to routine angiographic follow-up after stent implantation might have exaggerated the difference of TVR rates between CABG and EES patients. In fact, angiographic follow-up was performed in 61% after EES and 19% after CABG procedures. The new practice guidelines do not recommend routine angiographic surveillance even after left main coronary stenting (14, 26) . Therefore, our findings support the hypothesis of the ongoing randomized Evaluation of XIENCE PRIME versus the EXCEL (Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, that PCI using EES is clinically noninferior to CABG. Study limitations. First, the nonrandomized study design may have introduced biases into the results. Because we used a historical control group of SES patients, the stent techniques or medications in EES patients may have been improved or modified. For example, due to the less rigorous recommendation for routine angiographic follow-up, the rate of TVR for restenosis in patients without inducible ischemia may have been lower in EES than in SES patients. In addition, due to a lack of power calculation, this study may be underpowered in the comparison of clinical endpoints across the groups. Second, since we used the same inclusion criteria as the previous randomized study, our results may have limited generalizability in real-world practice. Third, the shorter follow-up duration in EES patients may have resulted in a lower incidence of adverse events than observed in SES patients. Finally, the 18-month follow-up period was not sufficient to assess the durable safety and efficacy of DES. To compensate for these limitations, a further randomized study with sufficient sample size and follow-up period is warranted.
Conclusions
We found that second-generation EES for ULMCA stenosis resulted in a similar risk of death, MI, stroke, or repeat revascularization as first-generation SES or CABG. Further randomized trials are needed to compare PCI using newergeneration DES and CABG in patients with these complex coronary lesions.
